Cargando…
Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis
AIM: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). METHODS: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immun...
Autores principales: | Boden, Elisa K, Canavan, James B, Moran, Christopher J, McCann, Katelyn, Dunn, William A, Farraye, Francis A, Ananthakrishnan, Ashwin N, Yajnik, Vijay, Gandhi, Roopali, Nguyen, Deanna D, Bhan, Atul K, Weiner, Howard L, Korzenik, Joshua R, Snapper, Scott B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690423/ https://www.ncbi.nlm.nih.gov/pubmed/31423487 http://dx.doi.org/10.1093/crocol/otz009 |
Ejemplares similares
-
Nanovesicles released by OKT3 hybridoma express fully active antibodies
por: Logozzi, Mariantonia, et al.
Publicado: (2021) -
Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
por: Roayaie, S, et al.
Publicado: (2000) -
Csak okt berben indul újra az LHC
Publicado: (2009) -
Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions
por: Cushing, Kelly C, et al.
Publicado: (2020) -
The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells
por: Maillard, Michel H., et al.
Publicado: (2007)